Phathom Pharmaceuticals (PHAT) Non Operating Income (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Non Operating Income for 9 consecutive years, with -$13.6 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Non Operating Income rose 14.28% year-over-year to -$13.6 million; the TTM figure through Jun 2026 stood at -$58.4 million (up 4.45% YoY), while the FY2025 annual figure was -$61.3 million, down 7.74% from the prior year.
• Non Operating Income advanced to -$13.6 million in Q2 2026 per PHAT's latest filing, from -$14.9 million in the prior quarter.
• Across five years, Non Operating Income topped out at -$2.8 million in Q1 2022 and bottomed at -$15.9 million in Q2 2025.
• Historically, Non Operating Income has averaged -$11.5 million across 5 years, with a median of -$13.3 million in 2024.
• Annual changes were most pronounced in 2022 — Non Operating Income slumped 350.69% — and 2026, when it advanced 14.28%.
• Phathom Pharmaceuticals' Non Operating Income stood at -$8.4 million in 2022, then slipped by 15.35% to -$9.7 million in 2023, then sank by 55.07% to -$15.0 million in 2024, then declined by 1.24% to -$15.2 million in 2025, then increased by 10.53% to -$13.6 million in 2026.
• Business Quant data shows PHAT's Non Operating Income at -$13.6 million in Q2 2026, -$14.9 million in Q1 2026, and -$15.2 million in Q4 2025.